Efficacy and safety of the CDK4/6 inhibitor palbociclib during different lines of treatment in patients with advanced stage endocrine sensitive/HER2 negative breast cancer. Background: Most of HR+ MBC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback